HGH Fragment 176-191
Peptide ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
HGH Fragment 176-191 is a synthetic C-terminal fragment of human growth hormone marketed for fat loss and lipolysis. It is not FDA-approved for any indication, is prohibited in sport as a GH fragment, and human fat-loss efficacy is not established. Published support is mainly adipocyte and animal work, with limited and mixed human development data for related AOD9604 formulations.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
HGH Fragment 176-191 is a peptide most often used for experimental anti-lipogenic activity in adipocyte models, related aod9604 studied for obesity, no approved human fat-loss benefit. NutriStack rates the overall evidence as insufficient. A typical adult dose is No FDA-approved human dose; no evidence-based supplement dose exists, commonly taken as not recommended for human use; laboratory research reagent only. This profile indexes 3 sources.
The bottom line
Evidence rating insufficient. Most-documented uses: experimental anti-lipogenic activity in adipocyte models, related aod9604 studied for obesity, no approved human fat-loss benefit. 3 sources indexed (1993–2013), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
The fragment corresponds to a C-terminal region of growth hormone reported to reduce lipogenesis and influence fat-cell lipid handling in experimental systems. It is not full growth hormone and should not be used to treat GH deficiency. Any injectable research product carries sterility, identity, and dosing uncertainty.3,2
Dosing & protocol.
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.
What it actually costs.
Real-world pricing across three quality tiers. Assumes Laboratory Research Reagent.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Full safety detail.
Side effects
- Injection-site reaction
- Headache
- Nausea
- Unknown long-term endocrine effects
- Product contamination or mislabeling risk
- Possible glucose variability in susceptible users
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
1- 1A double blind placebo controlled study of the effects of AOD9604 in overweight and obese subjectsStier H et al. · Journal of Endocrinology and Metabolism · 2013
Human evidence did not lead to approval
Mechanistic & preclinical
2- 2The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out miceHeffernan MA et al. · Endocrinology · 2001
Effects depended on animal model
- 3Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormoneWu Z et al. · Biochemical and Molecular Biology International · 1993
Reduced lipogenesis in experimental preparations
Common questions.
Quick answers about HGH Fragment 176-191, drawn from the data on this page.
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a synthetic C-terminal fragment of human growth hormone marketed for fat loss and lipolysis. It is not FDA-approved for any indication, is prohibited in sport as a GH fragment, and human fat-loss efficacy is not established. Published support is mainly adipocyte and animal work, with limited and mixed human development data for related AOD9604 formulations.
What is HGH Fragment 176-191 used for?
Commonly cited benefits of HGH Fragment 176-191 include: Experimental anti-lipogenic activity in adipocyte models; Related AOD9604 studied for obesity; No approved human fat-loss benefit; Does not substitute for growth hormone therapy. NutriStack rates the overall evidence as insufficient.
What is a typical dose of HGH Fragment 176-191?
A typical adult dose of HGH Fragment 176-191 is No FDA-approved human dose; no evidence-based supplement dose exists. The commonly recommended form is Not recommended for human use; laboratory research reagent only. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of HGH Fragment 176-191?
Reported side effects include injection-site reaction, headache, nausea, unknown long-term endocrine effects, product contamination or mislabeling risk, possible glucose variability in susceptible users. This is educational information; check with a healthcare professional before use.
How strong is the evidence for HGH Fragment 176-191?
NutriStack rates this as Insufficient, meaning the body of evidence reviewed in NutriStack's tiering framework. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
HGH Fragment 176-191 in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.